Skip to content
‹ Back to IndustriesSciences

On the Look-Out for Dry Eyes

Tears play a critical role in maintaining eye health beyond emotional expression, serving to lubricate and nourish the eye. Dry eye syndrome occurs when tear production or quality is insufficient, leading to discomfort and potential vision complications. Early detection and treatment are important for managing dry eye conditions effectively.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Featured · ·
Share
On the Look-Out for Dry Eyes

Key takeaways

01

Tears are essential for eye lubrication, nourishment, and overall eye health — not just emotional responses.

02

Dry eye syndrome is a common condition caused by insufficient tear production or poor tear quality.

03

Regular eye check-ups and early intervention can help identify and manage dry eye symptoms before they worsen.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

For most of us, tears are associated solely with crying. In a moment of sadness or joy, we might shed a few tears–but otherwise, the curious water in our eyes is not something we typically worry about. Tears, as it turns out, are essential to maintaining eye health, helping to lubricate and nourish the eye with every blink. Insufficient tearing, however, can result in dry eye, a chronic issue that is becoming increasingly prevalent.

While it is particularly common in older adults, dry eye affects anyone whose body either does not produce enough tears, or simply produces poor quality tears. This may seem like a minor annoyance, but dry eye can lead to some serious complications. For instance, the tears you produce help clear away dirt or harmful particles from your eyes, and without this cleansing process, eye infections gain a foothold. Even barring infection, a lack of tears can lead to abrasion on the surface of the cornea, vision problems and even corneal ulcers

The rise in popularity of LASIK surgery has brought the condition of dry eye into prevalence. For the best surgical outcome, it is important to be able to detect and control dry eye prior to the procedure. Luckily, there are several tests to help detect this condition.

The Schirmer Test is perhaps the most straight forward as it involves placing a very thin strip of paper under the lower eyelid in order to measure tear production. In what is known as the “tear breakup time” (TBUT) test, a small amount of dye is placed in the eye to monitor tear distribution. For those concerned about tests that directly interact with the eye’s surface, a keratometer can be used to analyze the tear film through imaging. And rounding out our list of the more common tests for dry eye is MMP-9 Testing, which involves taking a small sample of tears from the bottom lid. It is quick and painless, providing results in minutes as to whether a patient is ready for LASIK or if further treatment is needed.

Luckily, dry eye is very treatable. It all comes down to managing the quantity of tears produced or drained from the eyes. If too few tears are produced, over-the-counter artificial tear solutions are available, or your doctor may prescribe higher strength eye drops if a larger increase in tear production is necessary. If, however, tears are being drained too quickly through the tear ducts, silicone plugs can be used to block the ducts so that moisture is kept in the eye longer. Finally, dietary supplements such as flaxseed oil or Omega-3 fatty acids are also helpful in treating this condition.

While dry eye certainly is more common in those over the age of 65, it is something everyone should be aware of, as it is often caused by allergic reactions or even a medication you may be taking for an entirely different condition.

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

F
Featured
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Verdel's Q-2DMS aims to bring 2D mass spectrometry to more common hardware

Verdel's Q-2DMS aims to bring 2D mass spectrometry to more common hardware

Verdel and Warwick have developed a version of two-dimensional mass spectrometry called Q-2DMS. Until now, only the best-funded centers could afford 2DMS hardware, and Verdel's chief executive argues that the field lacked access, not an understanding of what the method can do. If 2DMS moves onto more common hardware, more labs could evaluate it. Published results show up to tenfold more usable spectral information on closely related or near-isobaric compounds, the look-alike molecules that separation and filtering tend to blur together or drop.

  • 01The reported gain of up to tenfold more usable spectral information applies to closely related or near-isobaric compounds, so the best trial samples are the mixtures chromatography struggles to separate.
  • 02A complete time-stamped record can be revisited after a sample runs out or degrades, and a full acquisition could, in principle, let archived runs address new questions later.

Oct 9, 2026

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

F
Featured

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512